Expert Q&A: The role of patient opinion leaders in drug development

Expert Q&A: The role of patient opinion leaders in drug development
December 12, 2021 YPrime

Pharma companies continue to seek out patient opinion leaders (POLs) to help them understand the wants and needs of patients. POLs can offer support throughout the drug development process in protocol development, identifying appropriate endpoints, optimising patient recruitment and retention strategies, contributing to patient management programmes and decision-making tools, raising disease state awareness, and disseminating information to Patient Advocacy Groups (PAGs). The patients’ voice is becoming louder and more impactful, and it will be essential for pharma to formulate POL engagement plans that are clear, transparent and ensure that patient needs are at the heart of drug development and access.

FirstWord spoke with Kelly Franchetti, RN, CCRN, CEN, Senior VP, Global Head Patient Insights and Strategy, YPrime, US, to discuss the important role that POL engagement will have on driving future drug development programmes.

Read the Full Article Below

PUBLISHED ARTICLE

Expert Q&A: The role of patient opinion leaders in drug development

Kelly Franchetti, RN CCRN CEN, Senior Vice President, Global Head Patient Insights & Strategy

RELATED CONTENT

Getting Better Together Initiative eCOA Lexicon

Getting Better Together Initiative eCOA Lexicon

How to Get the Most Out of Your eCOA Data

How to Get the Most Out of Your eCOA Data

Is BYOD right for your  eCOA Clinical Trial?

Is BYOD right for your eCOA Clinical Trial?

LATEST CONTENT

Strategies and Technologies that Empower DCTs

Strategies and Technologies that Empower DCTs

Put the power in the hands of patients with YPrime eConsent

Put the power in the hands of patients with YPrime eConsent

YPrime Launches eConsent Solution